Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis

Creative Commons License

Ascioglu S., Leblebicioglu H., VAHABOĞLU H., Chan K. A.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.66, no.6, pp.1215-1222, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 66 Issue: 6
  • Publication Date: 2011
  • Doi Number: 10.1093/jac/dkr136
  • Journal Name: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1215-1222
  • Keywords: haemorrhagic fever, antiviral therapy, mortality, INTRAVENOUS RIBAVIRIN, ORAL RIBAVIRIN, CLINICAL-FEATURES, CONTROLLED-TRIALS, RISK-FACTORS, DOUBLE-BLIND, EFFICACY, OUTBREAK, CHILDREN, MULTICENTER
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Background: Crimean-Congo haemorrhagic fever (CCHF) is a potentially fatal tick-borne infection. The virus is widely distributed around the world and reports of sporadic cases and outbreaks have recently increased significantly. Some authors have proposed that ribavirin improves survival in CCHF and this view appears to be widely accepted.